Susan Drinkwater
Adult Health · West Columbia, SCNPI 1487031860
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 97.7% of the total across 232 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 40 manufacturers, the largest accounting for just 15.3% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2022 at $1,782 and has fallen 95.9% since, to $74 in 2025.
Across 232 payments — averaging $16.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$591
- Neurocrine Biosciences, Inc.$510
- Teva Pharmaceuticals USA, Inc.$228
- Acadia Pharmaceuticals Inc$186
- AstraZeneca$172
- Eisai Inc.$170
- plus $2K from 34 others
What the payments were for
- Food & beverage$3,77798%
- Education$902%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 28 | $591 |
| Neurocrine Biosciences, Inc. | 51 | $510 |
| Teva Pharmaceuticals USA, Inc. | 25 | $228 |
| Acadia Pharmaceuticals Inc | 9 | $186 |
| AstraZeneca(2 entities) | 8 | $172 |
| Eisai Inc. | 9 | $170 |
| Novartis | 8 | $167 |
| Argenx US, Inc. | 6 | $154 |
| Lundbeck LLC | 6 | $150 |
| UCB, Inc. | 6 | $122 |
| Amgen(2 entities) | 7 | $111 |
| EMD Serono, Inc. | 5 | $100 |
| Acorda Therapeutics, Inc | 5 | $99 |
| Biohaven Pharmaceutical Holding Company Ltd. | 5 | $96 |
| Genentech USA, Inc. | 5 | $86 |
| SK Life Science, Inc. | 3 | $85 |
| Johnson & Johnson | 4 | $76 |
| Biogen | 4 | $66 |
| Pfizer | 4 | $61 |
| Neurelis, Inc. | 3 | $57 |
| Bristol Myers Squibb | 3 | $54 |
| Sanofi | 3 | $53 |
| Lilly USA, LLC | 3 | $46 |
| TG Therapeutics, Inc. | 2 | $43 |
| CSL Behring | 2 | $39 |
| ANI Pharmaceuticals, Inc. | 1 | $33 |
| Upsher-smith Laboratories LLC | 2 | $32 |
| Impel Pharmaceuticals Inc. | 2 | $31 |
| Kyowa Kirin, Inc. | 2 | $27 |
| MDD US Operations, LLC | 1 | $27 |
| Vanda Pharmaceuticals Inc. | 1 | $27 |
| Alnylam Pharmaceuticals Inc. | 1 | $24 |
| Biohaven Pharmaceuticals, Inc. | 1 | $22 |
| Pacira Pharmaceuticals Incorporated | 1 | $22 |
| Tanabe Pharma America, Inc. | 1 | $19 |
| Hospira, Inc. | 1 | $18 |
| Amneal Pharmaceuticals LLC | 1 | $18 |
| Avion Pharmaceuticals | 1 | $17 |
| Currax Pharmaceuticals LLC | 1 | $16 |
| Arbor Pharmaceuticals, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,867 in reported general payments places this provider in the 80th percentile of 292 adult health providers in South Carolina.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| NuplazidPimavanserin Tartrate | 12 | $68,763 |
| UbrelvyUbrogepant | 32 | $38,835 |
| Emgality PenGalcanezumab-Gnlm | 17 | $17,961 |
| Aimovig AutoinjectorErenumab-Aooe | 13 | $15,016 |
| Lacosamide | 14 | $5,704 |
| Levetiracetam | 85 | $5,695 |
| Sumatriptan Succinate | 45 | $2,336 |
| Pramipexole DihydrochloridePramipexole Di-Hcl | 45 | $1,764 |
| Memantine Hcl | 59 | $1,744 |
| Donepezil Hcl | 85 | $1,739 |
| Oxcarbazepine | 18 | $1,626 |
| Carbidopa-LevodopaCarbidopa/Levodopa | 48 | $1,580 |
| Topiramate | 36 | $975 |
| Primidone | 13 | $838 |
| Amitriptyline Hcl | 42 | $837 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Acadia Pharmaceuticals IncNuplazid | $186 | $68,76312 claims |
| AbbVieUbrelvy | $591 | $38,83532 claims |
| Upsher-smith Laboratories LLCTopiramate | $32 | $97536 claims |
| Lilly USA, LLCOlanzapine | $46 | $20612 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 292 adult health providers in South Carolina.
Other adult health in West Columbia
- Andrea OlsonWest Columbia$12K
- Christi WigginsWest Columbia$10K
- Leslee AunWest Columbia$8K
- Susan GriffinWest Columbia$8K
- Jennifer PeaglerWest Columbia$8K
- Latoya HintonWest Columbia$7K
- Shannon HallmanWest Columbia$7K
- Natalie O'KellyWest Columbia$7K
- Haleigh TaylorWest Columbia$6K
- Cecilia PorcherWest Columbia$6K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.